AI-Assisted Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction
Key facts
- Who runs it
- Hospital Universitario 12 de Octubre
- Where
- Spain2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 140 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Nov 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- AI-Assisted Remote Symptom Monitoring
- Standard of Care
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Histologically and/or cytologically confirmed diagnosis of advanced malignancy
- Considered to be at risk of developing MBO, defined as PMMBO yellow classification, or presenting a clinical diagnosis of MBO, characterized by clinical evidence of bowel obstruction (based on medical history, physical examination, and/or radiological assessment) distal to the ligament of Treitz, and deemed suitable for ambulatory management
- Receiving active oncologic therapy at the time of enrollment
- Able to understand and communicate effectively in Spanish
Who cannot take part
- Inability to understand and communicate in Spanish
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether artificial intelligence (AI)-assisted remote symptom monitoring can reduce hospital admissions related to malignant bowel obstruction (MBO) in patients with advanced cancer who have MBO or are at risk of developing MBO.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does AI-assisted remote symptom monitoring reduce the proportion of patients who experience at least one hospital admission due to MBO within 90 days? * Does AI-assisted remote symptom monitoring improve patient-reported outcomes, quality of life, healthcare resource utilization, and survival outcomes compared with standard care? Researchers will compare AI-assisted remote symptom monitoring plus standard care with standard care alone to determine whether remote monitoring can reduce MBO-related hospital admissions and improve patient outcomes.
Participants will receive study-specific assessments and follow-up for at least 90 days. Participants in the monitoring group will receive regular automated symptom-monitoring calls, and optional stool samples may be collected for microbiome research
The 2 groups in the trial
- AI- Assisted Remote Monitoring + Standard CareTreatment being tested
AI-Assisted Remote Symptom Monitoring An artificial intelligence-based conversational platform used to remotely assess symptoms associated with malignant bowel obstruction through automated telephone calls
Treatment: AI-Assisted Remote Symptom Monitoring
- Standard CareOther group
Routine clinical management and follow-up
Treatment: Standard of Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pragmatic Phase II Randomized Clinical Trial of Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction (MBO)
- Record updated
- 12 November 2026